High materiality7/10
Jazz Pharmaceuticals initiated with a Buy at Canaccord
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Canaccord Genuity initiated coverage on Jazz Pharmaceuticals with a Buy rating; target price $290; current price $242.18.
- Canaccord initiates JAZZ with Buy; PT $290; price $242.18.
- Upside to $290 (~20%).
Key facts
- 01
Target: $290
- 02
Posted price: $242.18
- 03
Analyst firm: Canaccord Genuity
- 04
Analyst: Gary Nachman
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.